Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
E-mail:
Web: www.cytokines.ru


  


Year 2018
1-4 issues

About journal

Current year
Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:
Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2012, No. 2

Subscribe for 2019 year

Order this issue

Order PDF of this article

Original Articles

Number 2'2012

The dynamics of the cytokine balance in patients with seronegative variant of rheumatoid arthritis during therapy with infliximab

T.A. Kalashnikova, L.P. Siziakina

Rheumatoid arthritis (RA) is an autoimmune disease caused by an imbalance of Th1, Th2 and ThIL-17 lymphocytes and predominance of proinflammatory cytokines TNFα, IL-1β, and IL-6. The most widely used drug in rheumatological practice is anti-TNFα-antibody (infliximab), but the prognosis of treatment and duration of anti-cytokine course to date are not sufficiently understood. In this study, immune status and cytokine production by immunocompetent cells were first evaluated in patients with seronegative articular form of RA during therapy with infliximab. Results. The algorithm was developed to predict the effectiveness of treatment with infliximab in patients with seronegative articular RA, which includes monitoring of immune system key parameters, as well as the content of the key proinflammatory cytokines (TNFα, IL-6, IL-1β) in serum and the peripheral blood mononuclear supernatants. The positive dynamics of these indicators during therapy reflects the effective infliximab therapy. (Cytokines and Inflammation. 2012. Vol. 11. № 2. P. 73–76.)

Keywords: infliximab, rheumatoid arthritis, anti-cytokine therapy, prognosis of effective therapy, cytokines, immune status.

Contents | Next article | Previous article


© 2007-2019 Cytokines and inflammation